Zealand Pharma A/S (ZEAL)

NASDAQ: ZEAL · Delayed Price · USD
13.84
1.05 (8.21%)
At close: May 25, 2022 4:00 PM
13.68
-0.16 (-1.16%)
After-hours:May 25, 2022 4:00 PM EDT
Market Cap603.90M
Revenue (ttm)44.33M
Net Income (ttm)-154.27M
Shares Out43.63M
EPS (ttm)-3.29
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,211
Open12.96
Previous Close12.79
Day's Range12.96 - 13.84
52-Week Range9.93 - 34.30
Beta1.25
AnalystsBuy
Price Target31.56 (+128.0%)
Earnings DateMay 12, 2022

About ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon du...

IndustryBiotechnology
IPO DateAug 9, 2017
CEOEmmanuel Dulac
Employees345
Stock ExchangeNASDAQ
Ticker SymbolZEAL
Full Company Profile

Financial Performance

In 2021, Zealand Pharma's revenue was 292.57 million, a decrease of -17.19% compared to the previous year's 353.31 million. Losses were -1.02 billion, 20.2% more than in 2020.

Financial numbers in millions DKKFinancial Statements

Analyst Forecast

According to 12 analysts, the average rating for ZEAL stock is "Buy." The 12-month stock price forecast is 31.56, which is an increase of 128.03% from the latest price.

Price Target
$31.56
(128.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

Company announcement – No. 24 / 20 2 2

14 hours ago - GlobeNewsWire

Why Zealand Pharma Shares Are Rising

Zealand Pharma A/S - ADR (NASDAQ: ZEAL) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital...

6 days ago - Benzinga

Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher

Zealand Pharma A/S (NASDAQ: ZEAL) has announced topline results from its second Phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI), a condition in which individual...

6 days ago - Benzinga

Zealand Pharma to seek FDA approval of its treatment for rare genetic disorder in babies

U.S.-listed shares of Zealand Pharma ZEAL, +1.83% ZEAL, +18.99% soared 21.2% in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment for...

6 days ago - Market Watch

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

Company announcement – No. 19  / 20 2 2

1 week ago - GlobeNewsWire

Zealand Pharma Provides Update on Refocused Strategy Prioritizing Research and Development

Company announcement – No. 18 / 2022

1 week ago - GlobeNewsWire

Zealand Pharma launches long-term incentive program for Zealand's Board of Directors for 2022

Company announcement – No. 14  / 20 2 2

1 month ago - GlobeNewsWire

Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022

Company announcement – No. 13  / 202 2

1 month ago - GlobeNewsWire

Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022

Company announcement – No. 13  / 202 2

1 month ago - GlobeNewsWire

Zealand Pharma's Annual General Meeting 2022

Company announcement – No. 12  / 20 2 2

1 month ago - GlobeNewsWire

Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference

Company announcement – No. 11  / 202 2

1 month ago - GlobeNewsWire

Zealand Pharma convenes its Annual General Meeting 2022

Company Announcement – No. 8 / 20 2 2

2 months ago - GlobeNewsWire

Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022

Company announcement – No. 5  / 2022

3 months ago - GlobeNewsWire

Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

4 months ago - Zacks Investment Research